Search - tctmd.com

Displaying 701 - 720 of 1042

Sort: Relevancy | Date

News Daily News

Ischemic Heart Disease the Leading Cause of Death Globally

Michael O'Riordan

September 19, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Daily News

Popular CV Risk Calculator Is Not Accurate Among Patients at Low Socioeconomic Standing

Yael L. Maxwell

August 31, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

Presentation ESC 2017

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Presenter: Anselm K. Gitt

August 30, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Presentation ESC 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Presenter: Paul M. Ridker

August 27, 2017

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

Presentation ESC 2017

Impact of BMI on Clinical Outcomes and Readmissions After Cardiac Catheterization

Presenter: Afnan Tariq

August 26, 2017

News Conference News ESC 2017

Underweight and Overlooked: Low BMI Patients May Be Highest-Risk Post-PCI

Shelley Wood

August 26, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

Advertisement

Ischemic Heart Disease the Leading Cause of Death Globally

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

TCTMD’s Top 10 Most Popular Stories for August 2017

Popular CV Risk Calculator Is Not Accurate Among Patients at Low Socioeconomic Standing

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Impact of BMI on Clinical Outcomes and Readmissions After Cardiac Catheterization

Underweight and Overlooked: Low BMI Patients May Be Highest-Risk Post-PCI

Evolocumab Not Cost-Effective at Current List Price

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content